Disulfidptosis-related lncRNAs for establishing a new prognostic model of endometrial carcinoma and drug sensitivity prediction: A retrospective observational cohort study
Year: 2026
Type: article
Abstract: Disulfidptosis is a novel mode of regulated cell death, but the prognostic role of disulfidptosis-related lncRNAs (DRLs) in uterine corpus endometrial carcinoma (UCEC) is unclear. Transcriptomic data from 552 UCEC tumor samples and 23 normal samples, together with clinical survival data, were obtained from The Cancer Genome Atlas. DRLs were screened by correlation analysis, Cox regression, and Least Absolute Shrinkage and Selection Operator. A prognostic model was constructed and validated. Functional enrichment, immune infiltration, mutation profiling, and drug sensitivity analyses were performed. A total of 397 DRLs were identified, and a 7-lncRNA signature (AL078644.1, Z99572.1, LINC00645, AC092794.1, AC004596.1, CDKN2B-AS1, AC013486.1) was developed. Patients were stratified into high-risk (n=275) and low-risk (n=264) groups, with significantly poorer survival in the high-risk group (P < .001). The model achieved area under the curve values of 0.781 (1-year), 0.741 (3-year), and 0.706 (5-year), and remained an independent prognostic factor in multivariate analysis (P < .01).Immune profiling revealed P < .05 in CD4+ memory T cells, macrophages M1, and dendritic cells, alongside altered Type I IFN response, APC co-inhibition, and inflammation. Mutation analysis showed distinct distributions of PTEN and TP53 between groups. Enrichment analysis indicated pathways related to microtubule-based movement, extracellular matrix organization, Wnt signaling, and neuroactive ligand-receptor interaction. Drug sensitivity analysis identified 22 compounds with significantly higher sensitivity in the high-risk group. We established a 7-DRL signature that independently predicts UCEC prognosis, reveals immune and molecular heterogeneity, and suggests potential candidate compounds for precision management.
Source: Medicine
Authors: Weijia Cheng, Manlin Zhang, Lili Jiang, Kuiran Liu
Institution: Sheng Jing Hospital
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,950
OpenAlex ID: W7226040978
